Table 1 Characteristics of included studies (N = 25)
Study ID/date | Study design | Time | Definition of high-risk PCa | Median age (RP vs RT) | Sample (n) | Comparison of treatments | Median follow-up | End-points |
|---|---|---|---|---|---|---|---|---|
Jayadevappa 2019 | R. cohort | 1996–2003 | GS ≥ 8 or T ≥ T2c | NA | 6296 | RP vs EBRT vs EBRT + BT | 10 years | OS/CSS |
Reichard 2019 | R. cohort | 2004–2013 | NCCN | 66 vs 61 | 304 | RP vs RT | 82.9 months | OS/MFS |
Caño-Velasco 2019 | R. cohort | 1996–2008 | EAU | 65 vs 71 | 286 | RP vs EBRT | RP: 152 months RT: 97 months | CSS/OS |
Muralidhar 2019 | R. cohort | 2004–2012 | GS: 9–10 | NA | 4367 2276 | RP+aRT vs EBRT+BT | 6.0 years (NCDB) 5.8 years (SEER) | OS |
Berg 2019 | R. cohort | 2004–2015 | NCCN | 58.15 vs 58.12 | 13985 | RP vs EBRT+BT | RP: 91 months EBRT+BT: 101 months | OS |
Tilki 2019 | R. cohort | 1992–2013 | GS: 9–10 | MaxRT: 70.34 RP: 66. 40 RP+aRT:66.64 MaxRP: 66.04 RP+ADT: 66.38 | 639 | RP vs RP+aRT vs MaxRP vs RP+ADT vs MaxRT | MaxRT: 5.51 years RP: 4.89 years RP + aRT: 3.87 years MaxRP: 4.88 years RP + ADT: 4.65 years | CSS/OS |
Jang 2018 | R. cohort | 1992–2009 | T ≥ T3 | NA | 13856 | RP+aRT vs RT | 14.6 years | CSS/OS |
Tyson 2018 | P. cohort | 2011–2012 | D’Amico | 65 | 2117 | RP vs EBRT | 3 years | QoL |
Ennis 2018 | R. cohort | 2004–2013 | NCCN | RP vs EBRT vs EBRT+BT: 62.61 vs 69.66 vs 67.15 | 42765 | RP vs EBRT vs EBRT+BT | 36.34 months | OS |
Gu 2018 | R. cohort | 2004–2008 | NCCN | 66 | 7656 | RP vs EBRT | NA | CSS/OS |
Markovina 2018 | R. cohort | 2002–2011 | NCCN | 62.9 vs 64.2 | 246 | RP vs EBRT | RP: 41 months RT: 51.4 months | OS/MFS |
Kishan 2018 | R. cohort | 2000–2013 | GS: 9–10 | RP vs EBRT vs EBRT+BT: 61 vs 67.7 vs 67.5 | 1809 | RP vs EBRT vs EBRT+BT 61 vs 67.7 vs 67.5 | RP: 4.2 years EBRT: 5.1 years EBRT + BT: 6.3 years | CSS/OS/MFS |
Robinson 2018 | R. cohort | 1998–2012 | NCCN | 63.1 vs 67 | 41953 | RP vs RT | RP: 7.3 years RT: 6.9 years | CSS |
Feldman 2017 | R. cohort | 1992–2009 | T3 | 71.76 vs 71.75 | 2935 | RP vs EBRT | RP: 11.47 years EBRT: 7.04 years | OS/CSS/QoL |
Ciezki 2017 | P. cohort | 1996–2012 | NCCN | LDRBT vs EBRT vs RP: 70 vs 68.5 vs 62 | 2557 | LDRBT vs EBRT vs RP | LDRBT: 48.9 months EBRT: 94.6 months RP: 55.6 months | BRFS/CSS/QoL |
Yamamoto 2015 | P. cohort | 2006–2010 | NCCN | 67 vs 71 | 150 | RP vs EBRT | 2 years | QoL |
Sun 2014 | R. cohort | 1992–2005 | T2c | 70 vs 73 | 67087 | RP vs RT vs WW | NA | OS/CSS |
Hoffman 2013 | R. cohort | 1994–1995 | PSA > 10 or GS 8–10 | NA | 1655 | RP vs EBRT | 15 years | OS/CSS |
Kibel 2012 | R. cohort | 1995–2005 | D’Amico | RP vs EBRT vs BT: 60 vs 69 vs 68(Clinic 1) 61 vs 70 vs 69(Clinic 2) | 10429 | RP vs EBRT vs BT | 67 months | OS/CSS |
Westover 2012 | R. cohort | 1988–2009 | D’Amico | 65 vs 70 | 657 | RP vs EBRT+BT | RP: 7.6 years EBRT + BT: 3.6 years | CSS |
Boorjian 2011 | R. cohort | 1988–2004 | NCCN | RP: 66 EBRT+ADT: 68.8 EBRT: 69.3 | 1847 | RP vs EBRT+ADT vs EBRT | RP: 10.2 years EBRT + ADT: 6.0 years EBRT: 7.3 years | OS/CSS |
Aizer 2009 | R. cohort | 1997–2005 | MSK/NCCN | NA | 556 | RP vs EBRT | RP: 46 months EBRT: 40 months | BRFS |
Takizawa 2009 | R. cohort | 1998–2004 | NCCN | 64.9 vs 71.1 | 162 | RP vs EBRT | 41 months | OS/BRFS/QoL |
Arcangeli 2009 | R. cohort | 2003–2007 | NCCN | 65.5 vs 75 | 284 | RP vs EBRT | RP: 33.8 months EBRT: 38.6 months | BRFS |
Akakura 2006 | RCT | 1989–1993 | T2b-3N0M0 | 68.1 vs 68.7 | 95 | RP vs EBRT | 102 months | BRFS/CSS/OS/QoL |